Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. [electronic resource]
Producer: 20200612Description: 796-803 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- genetics
- Camptothecin -- administration & dosage
- Class I Phosphatidylinositol 3-Kinases -- genetics
- Colorectal Neoplasms -- drug therapy
- Fluorouracil -- administration & dosage
- GTP Phosphohydrolases -- genetics
- Genotype
- Humans
- Leucovorin -- administration & dosage
- Male
- Membrane Proteins -- genetics
- Middle Aged
- Neoplasm Metastasis
- Panitumumab -- administration & dosage
- Prospective Studies
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins p21(ras) -- genetics
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.